Adaptive Biotechnologies Corporation
US ˙ NasdaqGS ˙ US00650F1093

SecurityADPT / Adaptive Biotechnologies Corporation
InstitutionNeuberger Berman Group LLC
Latest Disclosed Ownership110,664 shares
Latest Disclosed Value $ 1,536,016
Neuberger Berman Group LLC reports 75.49% decrease in ownership of ADPT / Adaptive Biotechnologies Corporation

On May 14, 2026 - Neuberger Berman Group LLC filed a 13F-HR form disclosing ownership of 110,664 shares of Adaptive Biotechnologies Corporation (US:ADPT) valued at $1,536,016 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 13, 2026 disclosing 451,569 shares of Adaptive Biotechnologies Corporation. This represents a change in shares of -75.49% during the quarter. The current value of the position is $1,769,517 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-05-14 2026-03-31 13F ADAPTIVE BIOTECHNOLOGIES Common 00650F109 110,664 -340,905 -75.49 1,536 -79.05 0.0006
2026-02-13 2025-12-31 13F ADAPTIVE BIOTECHNOLOGIES Common 00650F109 451,569 348,445 337.89 7,333 375.55 0.0055
2025-11-12 2025-09-30 13F ADAPTIVE BIOTECHNOLOGIES Common 00650F109 103,124 1,082 1.06 1,543 29.80 0.0011
2025-08-25 2025-06-30 13F/A-1 ADAPTIVE BIOTECHNOLOGIES Common 00650F109 102,042 62 0.06 1,189 56.94 0.0009
2025-08-13 2025-06-30 13F ADAPTIVE BIOTECHNOLOGIES Common 00650F109 102,042 62 1,189 0.0005
2025-05-13 2025-03-31 13F ADAPTIVE BIOTECHNOLOGIES Common 00650F109 101,980 -6,546 -6.03 758 16.46 0.0006
2025-02-13 2024-12-31 13F ADAPTIVE BIOTECHNOLOGIES Common 00650F109 108,526 0 0.00 651 17.12 0.0005
2024-11-14 2024-09-30 13F ADAPTIVE BIOTECHNOLOGIES Common 00650F109 108,526 3,323 3.16 556 46.05 0.0004
2024-11-14 2024-06-30 13F/A-1 ADAPTIVE BIOTECHNOLOGIES Common 00650F109 105,203 4,399 4.36 381 17.65 0.0003
2024-08-13 2024-06-30 13F ADAPTIVE BIOTECHNOLOGIES Common 00650F109 105,203 4,399 381 0.0003
2024-11-14 2024-03-31 13F/A-1 ADAPTIVE BIOTECHNOLOGIES Common 00650F109 100,804 -48,892 -32.66 324 -55.93 0.0003
2024-05-13 2024-03-31 13F ADAPTIVE BIOTECHNOLOGIES Common 00650F109 100,804 -48,892 324 0.0003
2024-11-14 2023-12-31 13F/A-2 ADAPTIVE BIOTECHNOLOGIES Common 00650F109 149,696 -273,770 -64.65 734 -68.23 0.0006
2024-02-09 2023-12-31 13F ADAPTIVE BIOTECHNOLOGIES Common 00650F109 149,696 -273,770 734 0.0006
2023-11-14 2023-09-30 13F ADAPTIVE BIOTECHNOLOGIES Common 00650F109 423,466 -131,311 -23.67 2,308 -38.02 0.0021
2023-08-11 2023-06-30 13F ADAPTIVE BIOTECHNOLOGIES Common 00650F109 554,777 -67,862 -10.90 3,723 -32.29 0.0033
2023-05-12 2023-03-31 13F ADAPTIVE BIOTECHNOLOGIES Common 00650F109 622,639 -8,230 -1.30 5,498 14.07 0.0051
2023-02-13 2022-12-31 13F ADAPTIVE BIOTECHNOLOGIES Common 00650F109 630,869 53,210 9.21 4,820 17.17 0.0047
2022-11-15 2022-09-30 13F ADAPTIVE BIOTECHNOLOGIES Common 00650F109 577,659 59,103 11.40 4,113 -1.95 0.0043
2022-08-15 2022-06-30 13F ADAPTIVE BIOTECHNOLOGIES Common 00650F109 518,556 -749,517 -59.11 4,195 -76.17 0.0042
2022-05-23 2022-03-31 13F/A-1 ADAPTIVE BIOTECHNOLOGIES Common 00650F109 1,268,073 -734,571 -36.68 17,601 -68.65 0.0149
2022-05-13 2022-03-31 13F ADAPTIVE BIOTECHNOLOGIES Common 00650F109 1,268,073 -734,571 17,546 0.0078
2022-02-11 2021-12-31 13F ADAPTIVE BIOTECHNOLOGIES Common 00650F109 2,002,644 -251,084 -11.14 56,143 -26.65 0.0440
2021-11-12 2021-09-30 13F ADAPTIVE BIOTECHNOLOGIES Common 00650F109 2,253,728 51,843 2.35 76,537 -14.72 0.0669
2021-08-13 2021-06-30 13F ADAPTIVE BIOTECHNOLOGIES Common 00650F109 2,201,885 99,140 4.71 89,752 6.04 0.0783
2021-05-13 2021-03-31 13F ADAPTIVE BIOTECHNOLOGIES Common 00650F109 2,102,745 93,441 4.65 84,638 -28.75 0.0808
2021-02-10 2020-12-31 13F ADAPTIVE BIOTECHNOLOGIES Common 00650F109 2,009,304 161,352 8.73 118,789 32.18 0.1232
2020-11-12 2020-09-30 13F ADAPTIVE BIOTECHNOLOGIES Common 00650F109 1,847,952 124,605 7.23 89,871 7.77 0.1066
2020-08-13 2020-06-30 13F ADAPTIVE BIOTECHNOLOGIES Common 00650F109 1,723,347 1,225,502 246.16 83,389 502.96 0.1037
2020-05-14 2020-03-31 13F ADAPTIVE BIOTECHNOLOGIES Common 00650F109 497,845 497,845 13,830 0.0211
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.